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Background: To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma
(PUC).
Patients and methods: A series of 124 patients (86 men, 38 women) were diagnosed with and underwent surgery for
PUC in 10 referral centers between 1993 and 2012. Kaplan–Meier analysis with log-rank testing was used to investigate
the impact of perioperative chemo(radio)therapy on overall survival (OS). The median follow-up was 21 months (mean: 32
months; interquartile range: 5–48).
Results: Neoadjuvant chemotherapy (NAC), neoadjuvant chemoradiotherapy (N-CRT) plus adjuvant chemotherapy
(ACH), and ACH was delivered in 12 (31%), 6 (15%) and 21 (54%) of these patients, respectively. Receipt of NAC/N-CRT
was associated with clinically node-positive disease (cN+; P = 0.033) and lower utilization of cystectomy at surgery
(P = 0.015). The objective response rate to NAC and N-CRT was 25% and 33%, respectively. The 3-year OS for patients
with objective response to neoadjuvant treatment (complete/partial response) was 100% and 58.3% for those with stable
or progressive disease (P = 0.30). Of the 26 patients staged ≥cT3 and/or cN+ disease, 16 (62%) received perioperative
chemo(radio)therapy and 10 upfront surgery without perioperative chemotherapy (38%). The 3-year OS for this locally
advanced subset of patients (≥cT3 and/or cN+) who received NAC (N = 5), N-CRT (N = 3), surgery-only (N = 10) and
surgery plus ACH (N = 8) was 100%, 100%, 50% and 20%, respectively (P = 0.016). Among these 26 patients, receipt of
neoadjuvant treatment was signiﬁcantly associated with improved 3-year relapse-free survival (RFS) (P = 0.022) and OS
(P = 0.022). Proximal tumor location correlated with inferior 3-year RFS and OS (P = 0.056/0.005).
Conclusion: In this series, patients who received NAC/N-CRT for cT3 and/or cN+ PUC appeared to demonstrate
improved survival compared with those who underwent upfront surgery with or without ACH.
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introduction
Primary urethral carcinoma (PUC) is an uncommon but poten-
tially lethal genitourinary malignancy that meets the deﬁnition
of a ‘rare cancer,’ accounting for well under 1% of all malignan-
cies. The estimated annual incidence of PUC is 650 new cases in
Europe (age-standardized ratio of 1.6/million in men and 0.6/
million in women), and based on an analysis of the Surveillance,
Epidemiology and End Results registry, the age-standardized
rate was reported to be three times higher in the United States
(4.3/million in men and 1.5/million in women) [1, 2].
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Prognosis of patients with PUC mainly depends on pathologic
tumor and nodal stage, with distal urethral tumors exhibiting sig-
niﬁcantly improved survival rates compared with proximal
tumors [3]. While surgery-only series have reported 5-year overall
survival (OS) rates in advanced PUC of only ∼40% [4], recent
retrospective studies have emphasized that modern platinum-
based polychemotherapeutic regimens can be effective in prolong-
ing survival even in lymph node-positive disease [5]. Yet, these
reports have also supported the critical role of consolidative
surgery after chemotherapy for achieving long-term survival in
patients with locally advanced urethral cancer [5]. Therefore, opti-
mizing treatment of advanced urethral cancer has recently
become the focus of international health care authorities aiming
at improving oncological efﬁcacy and quality of life of patients
with this disease [3].
Given the rarity of this cancer, there remain critical gaps in
our understanding of the optimal management of patients with
PUC. In particular, there are no reports we are aware of addres-
sing the timing of perioperative chemotherapy in patients with
clinically advanced PUC. In order to evaluate this clinical need,
we have assembled a multi-institutional collaborative with the
aim of determining the impact of neoadjuvant and adjuvant
treatment in patients undergoing surgery for PUC.
patients andmethods
patient cohort
In this Institutional-Review Board approved retrospective observational mul-
ticenter analysis, we reviewed the clinical and pathologic records of a total of
124 consecutive patients (86 men, 38 women) obtained from 10 prospectively
maintained databases who underwent surgery for PUC at 10 academic centers
between 1993 and 2012. Patients with evidence of distant metastatic disease
on cross-sectional imaging before primary treatment were excluded from
analysis.
perioperative treatment and assessment
of response
In order to understand the timing of perioperative chemotherapy, this study
assessed the subset of patients receiving neoadjuvant chemotherapy (NAC),
neoadjuvant chemoradiotherapy (N-CRT) and adjuvant chemotherapy (ACH)
around the time of surgical resection. Assessment of response to neoadjuvant
treatment was based on endoscopic and cross-sectional imaging ﬁndings. The
number of treatment cycles and the time interval between perioperative chemo
(radio)therapy and surgery was recorded. Objective response to neoadjuvant
chemo(radio)therapy was deﬁned as partial (PR) or complete response (CR) [5].
ACH was administered to the discretion of the treating physician based on
pathological risk factors in specimens. For those receiving N-CRT, a dose of 40–
45 Gy was delivered to the pelvic region by external beam radiotherapy with an
additional boost to the primary tumor of 20–24 Gy delivered either by intensity-
modulated radiation therapy or by brachytherapy. To better understand the role
of surgery in advanced stages, outcomes of patients who underwent surgery-
only for ≥cT3 and/or cN+ disease (N = 10) were additionally evaluated.
surgery
The modality of surgical treatment included transurethral resection, partial/
total urethrectomy and radical cystectomy with urethrectomy and urinary
diversion. Bilateral regional lymph node dissection (LND) was carried out at
the discretion of the treating surgeon based on intraoperative ﬁndings and
preoperative cross-sectional imaging. The level of LND was based on the
location of the primary tumor and typically included the inguinal lymph
nodes, external and internal iliac, obturator and common iliac lymph nodes.
clinical and histologic assessment
The following clinical and pathologic parameters were assessed: age at surgery,
gender, clinical and pathologic tumor stage, clinical and pathologic lymph
node tumor involvement, underlying histology, tumor grade, tumor location
(proximal versus distal), preoperative serum creatinine level, modality of
surgery for primary treatment and modality of treatment of recurrence. In
men, proximal tumor location was deﬁned as tumors located in the prostatic,
membranous or bulbar urethra and anteriorly when located in the penile
urethra and fossa navicularis. In women, proximal tumor location was deﬁned
as tumors located in the proximal two thirds of the urethra and anteriorly
when located in the distal third [6].
The histologic assessment was carried out at the center-speciﬁc pathology
department and was based on the WHO grading system and tumor–node–
metastasis classiﬁcation as approved by the AJCC [7]. The pathologic
macro- and microscopic evaluation of specimens included cross-sectioning
of the entire specimen with immunohistochemical staining to identify the
presence of urothelial, squamous cell and adenocarcinoma or rarer entities
[8]. Lymphovascular invasion was deﬁned as the presence of malignant cells
within an endothelial cell line [9].
follow-up
Electronic hospital charts and physician records were reviewed to determine
clinical outcomes. Patients generally were seen postoperatively at least every
3–4 months for the ﬁrst year, semiannually for the second and third years,
and annually thereafter. Follow-up examinations included cross-sectional
imaging with computed tomography or magnetic resonance imaging. In add-
ition to physical examination with laboratory testing, i.v. pyelography, cystos-
copy, urine cytology, urethral washings and bone scintigraphy were carried
out if indicated. Kaplan–Meier analysis with log-rank testing was used to in-
vestigate the impact of perioperative chemotherapy on relapse-free survival
(RFS) and OS. Relapse was deﬁned as either local recurrence in the surgical
ﬁeld, intraurethrally or in distant organs. For determining RFS, clinical out-
comes were measured from the date of surgery to the date of ﬁrst documented
relapse or last follow-up visit when the patients had not experienced relapse.
For OS, the date of death was determined by death certiﬁcates or hospital
charts or the last follow-up visit when patients were still alive [10].
statistical analysis
For univariable analysis, χ2 and Fisher’s exact tests were used for nominal
data and Student’s t-test for scaled data. Kaplan–Meier plots were used to es-
timate RFS and OS using log-rank testing.
P values are two-sided and P < 0.05 was considered signiﬁcant. Statistical
analysis was carried out using JMP® 11.0. Values are given as mean ± SEM
for normally distributed or as median (range) for non-normally distributed
variables.
results
In the total cohort (N = 124), the median follow-up was 21
months [mean: 32 months; interquartile range (IQR): 5–48,
total range: 3–200]. The median age at surgery was 66 years
(IQR: 58–76). Of the 124 patients, stage cT3 and/or cN+ was
present in 26 (21%). Of these 26 patients, 16 (62%) received
perioperative chemotherapy and 10 (38%) surgery without peri-
operative chemotherapy. A ﬂowchart describing the selection
process of the included patients is provided in supplementary
File S1, available at Annals of Oncology online.
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Perioperative chemotherapy was administered in 39 patients
(31%). Of these 39 patients, 12 (31%) received NAC, 6 (15%)
N-CRT plus ACH and 21 (54%) ACH. The different chemother-
apeutic regimens administered for perioperative chemotherapy
are listed in Table 1. The median number (total range) of cycles
of NAC, N-CRT and ACH was 3 (2–6), 3 (1–4) and 4 (2–6),
respectively (P = 0.52). The median time interval (total range, in
days) between surgery and NAC, N-CRT and ACH only was 36
(23–102), 80 (53–113) and 59 (28–600), P = 0.48, respectively.
The objective response rate to NAC and N-CRT (deﬁned as CR
or PR) was 25% and 33%, respectively (see Table 1). The 3-year
OS for patients with objective response to neoadjuvant treatment
(CR, PR) was 100% and 58.3% for those with stable disease or
progressive disease (P = 0.30).
Among patients treated with perioperative chemotherapy,
receipt of neoadjuvant chemo(radio)therapy was signiﬁcantly
associated with clinically node-positive tumor stage (cN+;
P = 0.046) and a lower utilization rate of radical cystectomy at
surgery (P = 0.015). No signiﬁcant associations were found
between the timing of perioperative chemotherapy and age,
gender, clinical and pathologic tumor stage, tumor location
(proximal versus distal), underlying histology, tumor grade,
preoperative serum creatinine level and modality of treatment of
relapse (see Table 2).
Relapse occurred in 23 of the 39 patients (59%) with a corre-
sponding 3-year RFS of 54%. In univariable analysis, RFS was
only signiﬁcantly associated with pathologically advanced
tumor stage (≥pT3, P = 0.034). There were a total of 12 (30.8%)
deaths during the study period, and OS was similarly only asso-
ciated with pathologically advanced tumor stage (P = 0.030). No
signiﬁcant associations were found between RFS/OS and modal-
ity and number of chemotherapy cycles administered, age,
gender, pathological nodal involvement, tumor location, tumor
grade, clinical tumor and nodal stage, histological subtype and
modality of treatment of relapse (see Table 3).
In the 39 patients receiving perioperative chemo(radio)
therapy, the type of chemotherapy (cisplatin- versus noncispla-
tin-based; 57.2% versus 57.8%; P = 0.63) and the number of
administered chemotherapeutic cycles (≥4 versus <4; 61.7% versus
48.9%, P = 0.34) were not associated with improved 3-year OS.
Among the 16 patients treated with perioperative chemother-
apy for cT3 and/or cN+ disease, the 3-year OS was 61%, respect-
ively. The 3-year OS for patients with ≥cT3 and/or cN+ disease
who received NAC (N = 5), N-CRT (N = 3), surgery-only
(N = 10) or surgery plus ACH (N = 8) was 100%, 100%, 50% and
20%, respectively (P = 0.016). Among these 26 patients, receipt of
neoadjuvant treatment was signiﬁcantly associated with improved
3-year RFS (P = 0.022) and OS (P = 0.022). Proximal tumor loca-
tion correlated with inferior 3-year RFS and OS (P = 0.056/0.005).
No signiﬁcant differences were found for other parameter listed
in Table 3.
discussion
The optimal timing of perioperative chemotherapy in patients
with advanced PUC is unknown. Since PUC is a rare tumor
entity, we set up a collaborative database and accrued a total of
124 cases to inform the role of perioperative chemotherapy. Of
these 124 patients, 39 received perioperative chemotherapy
(31%).
As would be expected, delivery of NAC was associated with
clinically node-positive disease. This ﬁnding suggests that the
decision making for NAC in this cohort was based on evidence
of nodal involvement at cross-sectional imaging. In our cohort,
patients with advanced clinical stage (≥cT3 and/or cN+) were
more likely to undergo perioperative chemotherapy before
surgery (62% versus 38%). Interestingly, patients with clinically
advanced tumor stage and/or node-positive disease exhibited
improved RFS and OS when treated in the neoadjuvant setting
with either NAC or N-CRT compared with patients treated only
with surgery or surgery plus ACH. Among the 39 patients, RFS
and OS were only associated with pathologically advanced
tumor stage at surgery but not with modality and duration
(cycles) of perioperative chemotherapy. These ﬁndings under-
line the prognostic impact of pathologic tumor extent after com-
pletion of perioperative chemotherapy. Although the objective
response rate of neoadjuvant treatment was relatively low, ad-
ministration of neoadjuvant treatment was associated with
Table 1. Chemotherapeutic regimens and response to neoadjuvant
treatment in the 39 patients undergoing perioperative treatment
of primary urethral carcinoma
NAC N-CRT +
ACH
ACH
Number of patients (%) 12 (31) 6 (15) 21 (54)
Mitomycin C/5-FU-based
Mitomycin C/5-FU 0 1 (SD) 0
5-FU only 0 0 1
Cisplatinum-based
Cisplatin/gemcitabine 2 (CR, PD) 2 (CR, PR) 4
Cisplatin/gemcitabine/paclitaxel 2 (PR, SD) 1 (PD) 1
Dose-dense MVAC 1 (PR) 0 0
MVAC 1 (PD) 0 0
Cisplatin/paclitaxel/ifosfamide 1 (PD) 0 1
Cisplatin/paclitaxel/5-FU 1 (SD) 0 0
Cisplatin/paclitaxel 1 (PD) 0 5
Cisplatin only 1 (PD) 1 (PD) 1
Carboplatinum-based
Paclitaxel/carboplatin/
gemcitabine
1 (PD) 0 0
Paclitaxel/carboplatin 0 0 1
Carboplatin/gemcitabine/
abraxane
1 (SD) 0 0
Carboplatin/paclitaxel/ifosfamide 0 0 2
Carboplatin/gemcitabine 0 0 1
Gemcitabine-based
Gemcitabine/paclitaxel 0 1 (PD) 1
Taxol/gemcitabine 0 0 1
Other regimens
Carmustin/IL-2 0 0 1
Dacarbazine 0 0 1
5-FU, 5-fluorouracil; ACH, adjuvant chemotherapy; CR, complete response;
IL-2, interleukin-2; MVAC, methotrexat/cisplatin/doxorubicin/vinblastin;
NAC, neoadjuvant chemotherapy; N-CRT, neoadjuvant chemoradio-
therapy; PR, partial response; PD, progressive disease; SD, stable disease.
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improved 3-year RFS and OS in the subset of patients with locally
advanced disease. Additionally, proximal tumor location was asso-
ciated with inferior RFS and OS which is in line with prior studies
[1, 2, 4]. These data suggest that patients with proximal tumor lo-
cation and clinically advanced stages may beneﬁt most from
neoadjuvant treatment. Despite the fact that patients treated with
neoadjuvant chemo(radio)therapy had similar rates of pathologic-
ally advanced stages and proximal tumor location at surgery com-
pared with patients treated with adjuvant therapy, they were less
likely to undergo cystectomy. Similar to bladder cancer [11], this
ﬁnding hints at the possibility that neoadjuvant chemo(radio)
therapy may exert a beneﬁcial impact on the primary tumor
extent and facilitate the surgical approach.
We found that OS rates in patients with clinically advanced
stages (≥cT3 and/or cN+) did not differ between those treated
either with NAC or with N-CRT plus ACH whereas ACH was
associated with decreased OS. The underlying histology did not
inﬂuence survival. These ﬁndings suggest that delivery of neoad-
juvant chemo(radio)therapy is critical for survival in advanced
stages. Owing to these ﬁndings and the low number of patients,
we combined patients treated with NAC and N-CRT plus ACH
into one group for ﬁnal survival analysis.
Although the number of included cases is low and the present
results have to be interpreted carefully, some meaningful con-
clusions can be drawn from these results. First, our ﬁndings
suggest that the presence of clinically enlarged lymph nodes
should alert clinicians of the possible presence of lymph node
metastatic disease, especially in case of advanced clinical tumor
stage and proximal tumor location, and should therefore be an
Table 2. Univariable Pearson’s χ2 Fisher’s exact test for clinical and
pathologic parameters in the 39 patients receiving perioperative
chemotherapy
NAC N-CRT +
ACH
ACH P value
Number of patients (%) 12 (31) 6 (15) 21 (54)
Follow-up time
Median 12 30 36 0.23
Mean 19 30 24
IQR 3–50 3–60 4–60
Gender
Male 9 (75.0) 3 (50.0) 14 (66.7) 0.57
Female 3 (25.0) 3 (50.0) 7 (33.3)
Age
Median 61 59 66 0.95
IQR 56–74 49–66 62–71
cT stage
cTX 0 (0) 0 (0) 0 (0) 0.10
cTa 1 (8.3) 0 (0) 2 (9.5)
cTis 0 (0) 0 (0) 0 (0)
cT1 2 (16.7) 1 (16.7) 6 (28.6)
cT2 5 (41.7) 2 (33.3) 5 (23.8)
cT3 2 (16.7) 2 (33.3) 3 (14.3)
cT4 2 (16.7) 1 (16.7) 5 (23.8)
cTa-T2 8 (66.7) 3 (50.0) 13 (61.9)
cT3-T4 4 (33.3) 3 (50.0) 8 (38.1)
pT stage
pT0 0 (0) 0 (0) 0 (0) 0.58
pTa 0 (0) 0 (0) 0 (0)
pTis 1 (8.3) 0 (0) 1 (4.8)
pT1 0 (0) 0 (0) 5 (23.8)
pT2 5 (41.7) 2 (33.3) 6 (28.6)
pT3 5 (41.7) 1 (16.7) 2 (9.5)
pT4 1 (8.3) 3 (50.0) 7 (33.3)
pTa-T2 6 (50.0) 2 (33.3) 12 (57.1)
pT3-T4 6 (50.0) 4 (66.7) 9 (42.9)
cN stage
cNX 3 (25.0) 2 (33.3) 0 (0) 0.046
cN0 5 (41.7) 2 (33.3) 17 (81.0)
cN+ 4 (33.3) 2 (33.3) 4 (19.0)
pN stage
pNX 6 (50.0) 2 (33.3) 7 (33.3) 0.07
pN0 3 (25.0) 1 (16.7) 12 (57.1)
pN1-2 3 (25.0) 3 (50.0) 2 (9.5)
Tumor grade at primary diagnosis
G1 0 (0) 1 (16.7) 0 (0) 0.18
G2 3 (25.0) 0 (0) 3 (14.3)
G3 9 (75.0) 5 (83.3) 18 (85.7)
Histology
UC 4 (33.3) 1 (16.7) 12 (57.1) 0.23
SCC 5 (41.7) 3 (50.0) 3 (14.3)
AC 2 (16.7) 2 (33.3) 2 (9.5)
Mixed 1 (8.3) 0 (0) 2 (9.5)
Unclassified 0 (0) 0 (0) 2 (9.5)
Tumor location
Proximal 7 (58.3) 3 (50.0) 14 (66.7) 0.44
Distal 5 (41.7) 3 (50.0) 7 (33.3)
Continued
Table 2. Continued
NAC N-CRT +
ACH
ACH P value
Preoperative serum creatinine level (mg/dl)
Median 0.9 0.9 1.0 0.70
Mean 1.0 0.9 1.0
IQR 0.8–1.2 0.7–1.1 0.7–1.2
Surgical modality of primary treatment
TUR only 1 (8.3) 0 (0) 5 (23.8) 0.015
Partial urethrectomy 0 (0) 1 (16.7) 0 (0)
Urethrectomy 5 (41.7) 2 (33.3) 5 (23.8)
Cyst(oprostat)ectomy
plus urethrectomy
3 (25.0) 0 (0) 11 (52.4)
Other 3 (25.0) 3 (50.0) 0 (0)
Modality of treatment of local/urethral relapse
Surgery 3 (25.0) 0 (0) 3 (14.3) 0.41
Radiotherapy 3 (25.0) 0 (0) 3 (14.3) 0.63
Chemotherapy 0 (0) 0 (0) 0 (0) –
Receipt of palliative
(systemic)
chemotherapy
3 (25.0) 1 (16.7) 9 (42.9) 0.36
AC, adenocarcinoma; ACH, adjuvant chemotherapy; IQR, interquartile
range; NAC, neoadjuvant chemotherapy; N-CRT, neoadjuvant chemora-
diotherapy; SCC, squamous cell carcinoma; TUR, transurethral resec-
tion; UC, urothelial carcinoma.
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Table 3. Relapse-free and overall survival for patients treated with or without perioperative chemo(radio)therapy according to clinical and pathologic tumor characteristics
Parameters Total cohort with perioperative chemotherapy (N = 39) cT3 and/or cN+ (with or without perioperative chemotherapy) (N = 26)
RFS OS RFS OS
RR (95% CI) P value RR (95% CI) P value RR (95% CI) P value RR (95% CI) P value
NAC/N-CRT plus ACH versus ACH only 0.91 (0.42–1.90) 0.97 0.98 (0.32–2.96) 0.80 0.14 (0.01–0.78) (for
NAC/N-CRT plus ACH
versus ACH/surgery-only)
0.022 0.10 (0.01–0.71) (for
NAC/N-CRT plus ACH
versus ACH/surgery-only)
0.024
≥pT3 versus ≤pT2 2.6 (1.1–6.8) 0.030 5.5 (1.2–35.4) 0.034 1.23 (0.43–4.47) 0.70 1.02 (0.22–7.16) 0.98
≥cT3 versus ≤cT2 2.1 (0.9–5.3) 0.26 2.3 (0.5–9.7) 0.10 – – – –
cN+ versus cN0 2.5 (0.8–7.2) 0.25 2.5 (0.5–11.6) 0.11 – – – –
cNX versus cN0 4.1 (0.2–28.9) 0.17 7.0 (0.3–68.39) 0.28 – – – –
Tumor location proximal versus distal 1.9 (0.7–5.4) 0.35 2.1 (0.5–14.3) 0.20 2.33 (0.98–5.95) 0.056 10.11 (1.82–188.90) 0.005
Tumor grade G1/G2 versus G3 2.3 (0.7–10.0) 0.21 3.2 (0.6–59.8) 0.17 5.97 (0.57–50.61) 0.13 4.66 (0.84–86.90) 0.08
Histology
UC versus SCC 0.7 (0.2–2.6) 0.49 1.1 (0.1–22.0) 0.53 1.10 (0.41–3.04) 0.84 2.17 (0.41–15.95) 0.36
UC versus AC 0.3 (0.1–1.4) 0.84 0.8 (0.1–16.2) 0.13 0.66 (0.04–3.71) 0.68 0.01 (0–3.27) 0.23
Gender
Male versus female 0.6 (0.2–1.7) 0.13 0.3 (0.1–1.4) 0.32 1.23 (0.54–2.86) 0.61 0.54 (0.11–2.05) 0.36
Age
>65 years versus ≤65 years 1.7 (0.5–6.4) 0.59 1.6 (0.3–11.4) 0.38 1.48 (0.59–3.76) 0.39 1.23 (0.29–5.22) 0.77
Treatment of relapse
Surgery – – 0.4 (0.1–1.2) 0.08 – – 0.19 (0.01–1.17) 0.07
Radiotherapy – – 0.3 (0–1.5) 0.15 – – 2.28 (0.31–11.76) 0.31
Palliative (systemic) chemotherapy – – 1.4 (0.6–3.4) 0.42 – – 2.56 (0.52–10.50) 0.22
Bold values indicate statistically significant difference.
AC, adenocarcinoma; ACH, adjuvant chemotherapy; BSC, best supportive care; OS, overall survival; RFS, relapse-free survival; RR, relative risk; SCC, squamous cell carcinoma; UC, urothelial carcinoma.
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impetus to deliver neoadjuvant chemo(radio)therapy. This
ﬁnding is in line with studies reporting a high degree of con-
cordance between clinical and pathological staging in PUC [3].
Another explanatory approach for the worse prognosis of patients
with ACH may be that utilization of radical cystectomy with
urinary diversion adversely affects performance status and post-
operative renal function thereby delaying timely delivery of
chemotherapy after surgery [11]. However, in our cohort, pre-
operative serum creatinine levels were not different between the
three groups which suggests that renal function did not impact
on the decision making for perioperative treatment.
Similar to our ﬁndings, a prior series reported outcomes in
44 patients treated uniformly with chemotherapy without radio-
therapy for advanced primary urethral cancer with squamous
cell carcinoma (SCC) and adenocarcinoma being the most
prevalent histological entities. Patients were subjected to speciﬁc
cisplatin-based polychemotherapeutic regimens according to
the underlying histology. The overall response rate for the
various regimens was reported to be much higher with 72%.
The median OS of the entire cohort was 32 months. Of note,
patients who underwent surgery after chemotherapy had signiﬁ-
cantly improved OS compared with those who were managed
with chemotherapy alone [5].
Another recent series reported that CR to concurrent che-
moradiotherapy (consisting of two cycles of 5-ﬂuorouracil/mito-
mycin C and 45–55 Gy over the span of 5 weeks) in T3 SCC of
the urethra was observed in 79% of the patients. Consolidation
surgery was, however, only initiated if patients never responded
to their ‘modiﬁed Nigro-protocol’ or developed local recurrence.
Despite the high primary response rate of ∼80%, the corre-
sponding 5-year disease-free and OS rates were moderate with
43% and 52% [12].
In our series, we found that the 3-year OS rate in patients
with ≥cT3 and/or cN+ stage was relatively high at 61%. Of note,
all patients treated with NAC/N-CRT were alive after 5 years.
Therefore, these data suggest that consolidation surgery may be
of prognostic importance at the time of completion of neoadju-
vant chemo(radio)therapy which may also obviate the need for
aggressive salvage surgery in case of relapse. In terms of the
effects of salvage treatment on OS, we found that neither surgery
nor radiotherapy exerted a beneﬁcial impact on survival. These
data highlight, once more, the importance of the decision making
for primary treatment in advanced PUC. In this regard, we re-
cently reported that clinical nodal stage is a strong predictor for
oncological outcomes in primary urethral cancer [13].
Our study has several limitations inherent to the retrospective,
small size, and multicenter nature of the analysis, which of
course is requisite given the rarity of the disease. Possible biases
include absence of regional LND in approximately half of the
patients and interobserver variabilities in the clinical staging
and pathological assessment of specimens. We could not adjust
for patient preferences, toxicities of perioperative treatment and
comorbidities which may have impacted on the clinical decision
making for either NAC or ACH. In this regard, an important
alternative explanation for these ﬁndings is that patients who
were healthier (with better renal function) received neoadjuvant
chemo(radio)therapy and less healthy patients did not, particu-
larly in the setting of advanced disease. Yet, preoperative serum
creatinine levels were not different between the three groups
and all patients were ﬁt enough to undergo either ACH after
surgery or neoadjuvant treatment before surgery. In addition, all
patients were treated in academic centers by multidisciplinary
teams dedicated to the management of lower urinary tract
cancer. Notwithstanding, owing to these limitations, the results
of this multicenter pooled analysis provide new insights into the
management of this rare disease and await further prospective
validation.
This is, to our knowledge, the ﬁrst series that demonstrates
the prognostic beneﬁt of NAC and N-CRT with ACH in a con-
secutive series of patients who underwent perioperative chemo-
therapy plus surgery for advanced PUC. Further studies should
yield a better understanding of how perioperative chemotherapy
exerts a positive effect on survival in order to selectively advo-
cate its use in advanced PUC.
conclusion
In this series, patients who received NAC or chemoradiotherapy
for locally advanced PUC (≥cT3 and/or cN+) appeared to dem-
onstrate improved survival compared with those who underwent
upfront surgery with or without ACH.
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